PPIA and cancer: We also identify a set of genetic vulnerabilities associated with CYPA loss and inhibition, exposed by this altered DNA-R landscape, before exploring examples of how CYPA inhibition may have clinical efficacy in a defined set of cancers with a shared genome instability profile involving aberrantly elevated/addiction to HRR.